A Phase II trial of Intercept Pharmaceuticals' (ICPT) obeticholic acid (OCA) for the treatment of a chronic liver disease called nonalcoholic steatohepatitis (NASH) has been stopped early due to the therapy meeting the primary endpoint of the trial.
NASH is caused by excessive fat accumulation in the liver, and can lead to cirrhosis, eventual liver failure and death. No drugs have been approved for the treatment of NASH.
"On its current trajectory, the disease is projected to become the leading indication for liver transplant," Intercept says.
Shares skyrocket 109%. (PR)